Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)

NCT07730528 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
10
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Humacyte, Inc.